Targeting NTMT1 to help people with muscular dystrophy
Official title: Targeting protein N-terminal methyltransferase in muscle diseases
Funded at Purdue University · NIH-11466147 · Data updated 2026-11-12
A researcher team at Purdue is testing a new druggable target called NTMT1 to help muscle repair in Duchenne muscular dystrophy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project start | September 15, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $587,757 |
| NIH project number | 1R01AR088525-01 |
| Project ID | NIH-11466147 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with Duchenne muscular dystrophy or muscle cells derived from DMD patients suitable for laboratory studies.
✕Less likely to help
Patients without DMD or with unrelated conditions may not benefit from this specific research.
What this research studies
This project focuses on a protein modifier called NTMT1 that may be blocked to improve muscle stem cell function and muscle regeneration. Researchers will optimize NTMT1 inhibitors for better strength, safety, and how long they stay in the body. They will study effects in mice and in human DMD muscle cells to understand how NTMT1 inhibition could boost muscle repair. The work combines chemistry, biology, and advanced profiling to determine if NTMT1 could become a new treatment for DMD.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic approach that improves muscle strength and repair for people with Duchenne muscular dystrophy.
How similar studies have gone: Preclinical data in mouse models and human myoblasts suggest NTMT1 inhibition can enhance muscle regeneration, supporting potential benefits.
Where this research is happening
-
Purdue University
West Lafayette, United States Active
Researchers
- Principal investigator: Huang, Rong — Purdue University
- Study coordinator: Huang, Rong
Related research
Other NIH-funded projects on the same topics.
-
Meltblown scaffolds to help irreparable rotator cuff tears
A new 3-D biomaterial scaffold made from meltblown technology aims to improve interposition grafts for people with irreparable rotator cuff tears.
-
Targeting how RMS cells fail to mature to slow or stop pediatric muscle cancer spread
A project to understand why a pediatric muscle cancer called rhabdomyosarcoma spreads, and to test ideas that could slow or stop it by helping cancer cells mature properly.
-
Risk stratification of malaria in school-age children using mobile eye-based spectroscopy
A low-cost, phone-based method uses pictures of the inner eyelid to identify which children in high-risk areas should get malaria tests.
-
Dual-AAV gene replacement approach for SCN2A-related neurodevelopmental disorders
A gene therapy approach using two AAV vectors to restore SCN2A function in children with SCN2A-related neurodevelopmental disorders.
-
Personalized use of newer diabetes medicines for Type 2 diabetes
Aiming to tailor use of newer glucose-lowering drugs for people with type 2 diabetes to improve health and access in real-world settings.
-
Intelligent social risk management for people with Alzheimer's and related dementias
Aimed at people living with dementia, this project uses AI and real-world health data to identify and address social factors that affect their care and quality of life.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.